BioCryst Pharmaceuticals secured a $69 million contract with the U.S. Department of Health and Human Services to supply RAPIVAB® for influenza treatment over five years. The agreement aims to strengthen the Strategic National Stockpile for emergencies, with an initial order placed for 19,125 doses.